Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response

In breast cancer (BC), up to 10–20% patients were known to have clinical benefit with immune checkpoint inhibitors, and biomarkers are needed for optimal use of this multi-potential therapeutic strategy. Accordingly, we conducted an experiment to identify expression of genes associated with immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Lee, Eunjin, Park, Kyunghee, Park, Woong-Yang, Jung, Hae Hyun, Ahn, Jin Seok, Im, Young-Hyuck, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564574/
https://www.ncbi.nlm.nih.gov/pubmed/28537889
http://dx.doi.org/10.18632/oncotarget.17653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564574/
https://www.ncbi.nlm.nih.gov/pubmed/28537889
http://dx.doi.org/10.18632/oncotarget.17653

Ejemplares similares